Multitude Therapeutics Inc.
Clinical trials sponsored by Multitude Therapeutics Inc., explained in plain language.
-
New cancer drug AMT-676 enters first human tests
Disease control Recruiting nowThis early-phase trial tests AMT-676, a drug designed to seek out and destroy cancer cells that carry a protein called CDH17. It is given intravenously to 24 adults with advanced solid tumors (such as colorectal, gastric, or pancreatic cancer) that have not responded to prior tre…
Phase: EARLY_PHASE1 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug AMT-253 enters human trials for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the dr…
Phase: PHASE1, PHASE2 • Sponsor: Multitude Therapeutics Inc. • Aim: Disease control
Last updated Jun 26, 2026 13:59 UTC